Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novartis, Glenmark...

    Novartis, Glenmark enter partnership to commercialize, distribute respiratory drugs Seebri, Onbrize, Ultibro

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-06-24T15:02:00+05:30  |  Updated On 24 Jun 2019 9:32 AM GMT
    Novartis, Glenmark enter partnership to commercialize, distribute respiratory drugs Seebri, Onbrize, Ultibro

    Under the terms of the agreement, Novartis will remain the holder of the registration of the drugs Seebri, Onbrize and Ultibro and will be responsible to manufacture them with all technical excellence in line with its global commitment to quality, effectiveness and safety


    New Delhi: Drug major Glenmark Pharmaceuticals Monday said its subsidiary Glenmark Farmacutica has entered into an exclusive partnership agreement with Novartis Biosciences SA for three respiratory products in Brazil.


    The products involved in the agreement are Seebri (Glycopyrronium bromide), Onbrize (Indacaterol) and Ultibro (combination of Indacaterol and Glycopyrronium), which are indicated for relief of symptoms in adults with chronic obstructive pulmonary disease (COPD).










    Under the terms of the agreement, Novartis will remain the holder of the registration of these medicines and will be responsible to manufacture them with all technical excellence in line with its global commitment to quality, effectiveness and safety, Glenmark said in a regulatory filing.


    Also Read: Novartis MS drug Mayzent price out of line with benefit; says US group








    Glenmark will be responsible for promoting, commercialising and distributing of these products in Brazil, the company added.


    This agreement will be effective from July 1, 2019 onwards.


    Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said this arrangement with Novartis Biosciences SA will strengthen its respiratory franchise in Brazil.


    "This partnership is in line with our vision to expand our respiratory product offerings for patients and prescribers in Brazil and further consolidate our position in this segment," Saldanha said.


    Also Read: Novartis’ secret settlement talks revealed in accidental filing: Bloomberg Report

    Brazil breathing problem Chronic Obstructive Pulmonary Disease COPD Glenmark Glenn Saldanha Novartis Novartis AG Onbrize partnership agreement pharma pharma news pharmanews india Respiratory drugs respiratory products Seebri Ultibro 
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      FDA seizes unlicensed medical devices worth over Rs 1 crore from GT Hospital

      FDA seizes unlicensed medical devices worth over Rs 1 crore from GT Hospital

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Apollo medical centre in Oman granted hospital status

      Apollo medical centre in Oman granted hospital status

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      3.36% of about 82,600 drugs samples found to be substandard

      3.36% of about 82,600 drugs samples found to be substandard

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs 9700 crore

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs...

      Aurobindo Pharma receives USFDA approval to manufacture ADHD drug

      Aurobindo Pharma receives USFDA approval to manufacture ADHD drug

      Calcutta HC sets aside Centers decision for strategic sale of Bengal Chemicals

      Calcutta HC sets aside Center's decision for strategic sale of Bengal Chemicals

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 27 May 2022 6:45 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X